What it is
A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist available as a once-weekly subcutaneous injection or once-daily oral tablet.
How it works
Activates GLP-1 receptors, augmenting glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite via central pathways.
Where it's used
Used in type 2 diabetes for glycemic control (Ozempic, Rybelsus) and in chronic weight management (Wegovy).
FDA-approved use
Type 2 diabetes mellitus (Ozempic, Rybelsus); chronic weight management in adults with obesity or overweight with comorbidity (Wegovy); cardiovascular risk reduction in type 2 diabetes.
Tracking it
Semaglutide is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem. with a half-life of about 7 days (168 h), a dose log also lets a tracker model the relative amount still in your system between doses. for titrated compounds like this one, a log that records the dose at each step is the difference between knowing your history and guessing it.
Source
OpenFDA
Last reviewed 2026-06-11